Rare diseases
Investigational molecules
Locations
Study of Oxaliplatin and Nivolumab for Patients with Metastatic Colorectal Cancer
NorwayStudy Comparing Nivolumab to Placebo for Patients with High-Risk Invasive Bladder Cancer
AustriaStudy of Nivolumab, Ipilimumab, and UV1 Vaccine for Patients with Malignant Pleural Mesothelioma After Initial Chemotherapy
DenmarkStudy on High-Dose Vitamin C with Ipilimumab and Nivolumab for Patients with Colorectal Cancer
ItalyStudy of Nivolumab and Ipilimumab for Patients with Stage 3 Non-Small Cell Lung Cancer Not Suitable for Surgery
BelgiumStudy on the Effect of DA-EPOCH-R and Nivolumab in Patients with Newly Diagnosed High-Grade B-Cell Lymphoma with MYC and BCL2/BCL6 Rearrangements
BelgiumStudy Comparing Nivolumab with Ipilimumab or Nivolumab with Chemotherapy to Chemotherapy Alone in Patients with Early Stage Non-Small Cell Lung Cancer
FranceStudy on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma
AustriaStudy of BMS-986408 Alone or with Nivolumab and Ipilimumab for Patients with Advanced Solid Tumors
FranceStudy of Relatlimab and Nivolumab for Patients with Advanced Liver Cancer Who Have Not Received Immunotherapy After Tyrosine Kinase Inhibitor Treatment
CzechiaStudy of Subcutaneous Nivolumab with or without Recombinant Human Hyaluronidase PH20 for Patients with Lung, Kidney, Melanoma, Liver, Colorectal, or Bladder Cancer
FranceStudy of BMS-986442 and Nivolumab, Alone or with Chemotherapy, for Patients with Advanced Solid Tumors and Non-Small Cell Lung Cancer
ItalyTell us about your condition – we search every trial in Europe and connect you with the right site.
